Single-dose versus fractionated radioimmunotherapy: Model comparisons for uniform tumor dosimetry

Journal of Nuclear Medicine

Volumn 41, Issue 3, 2000, Pages 538-547

  O'Donoghue, Joseph A ^a   Sgouros, George ^a   Divgi, Chaitanya R ^a   Humm, John L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cure; Fractionation; Gompertzian growth; Mathematical model; Radioimmunotherapy; Remission; Tumor response

Indexed keywords

IODINE 131; MONOCLONAL ANTIBODY;

ARTICLE; CANCER SURVIVAL; ISOTOPE LABELING; KIDNEY CARCINOMA; MATHEMATICAL MODEL; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIATION DOSE FRACTIONATION; RADIOIMMUNOTHERAPY; RADIOISOTOPE DISTRIBUTION; RADIOSENSITIVITY; TUMOR VOLUME;

DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MODELS, THEORETICAL; NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE;

EID: 0034051611     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Caron PC, Jurcic JG, Scott AM, et al. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood. 1994;83:1760-1768.
2. Knox S, Hoppe RT, Maloney D, et al. Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Blood. 1996;87:893-899.
3. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, et al. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol. 1997;15:1529-1537.
4. Bentzen SM, Johansen LV, Overgaard J, Thames HD. Clinical radiobiology of squamous cell carcinoma of the oropharynx. Int J Radiat Oncol Biol Phys. 1991;20:1197-1206.
5. Fowler JF, Lindstrom MJ. Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys. 1992;23:457-467.
6. Petereit DG, Sarkaria JN, Chappell R, et al. The adverse effect of treatment prolongation in cervical carcinoma. Int J Radiat Oncol Biol Phys. 1995;32:1301-1307.
7. Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988;27:131-146.
8. Trott KR. Cell repopulation and overall treatment time. Int J Radiat Oncol Biol Phys. 1990;19:1071-1075.
9. Fowler JF. The phantom of tumor treatment: continually rapid proliferation unmasked. Radiother Oncol. 1991;22:156-158.
10. Wheldon TE, O'Donoghue JA. The radiobiology of targeted radiotherapy. Int J Radiat Biol. 1990;58:1-21.
11. Dale RG. Dose-rate effects in targeted radiotherapy. Phys Med Biol. 1996;41:1871-1884.
12. 90Y-labeled B72.3 GYK-DTPA immunoconjugate in beagle dogs. Nucl Med Biol. 1993;20:571-578.
13. Schlom J, Molinolo A, Simpson JF, et al. Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. J Natl Cancer Inst. 1990;82: 763-771.
14. 131I-labeled monoclonal antibody CC49. Cancer Res. 1995;55(suppl):5881s-5887s.
15. Sun LQ, Vogel CA, Mirimanoff RO, et al. Timing effects of combined radioimmunotherapy and radiotherapy on a human solid tumor in nude mice. Cancer Res. 1997;57:1312-1319.
16. O'Donoghue JA. The response of tumors with Gompertzian growth kinetics to fractionated radiotherapy. Int J Radiat Biol. 1997;72:325-339.
17. 131I-G250 antibody in patients with renal cell carcinoma. J Nucl Med. 1998;39:484-489.
18. Steel GG. Cellular sensitivity to low dose-rate irradiation focuses the problem of tumour radioresistance. Radiother Oncol. 1991;20:71-83.
19. International Commission on Radiological Protection. Report of the Task Group oan Reference Man. ICRP publication 23. New York, NY: Pergamon Press; 1975.
20. Loevinger R, Budinger TF, Watson EE. MIRD Primer for Absorbed Dose Calculations. New York, NY: The Society of Nuclear Medicine; 1988.
21. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med. 1993;34:689-694.
22. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996;37:538-546.
23. Divgi CR, Bander NH, Scott AM, et al. Phase I/III radioimmunotherapy trial with iodine-131 labeled monoclonal antibody (MAb) G250 in metastatic renal cell carcinoma. Clin Cancer Res. 1998;4:2729-2739.
24. Steel GG, McMillan TJ, Peacock JH. The radiobiology of human cells and tissues: in vitro radiosensitivity - the picture has changed in the 1980s. Int J Radiat Biol. 1989;56:525-537.
25. Weichselbaum RR, Rotmensch J, Ahmed-Swan S, Beckett MA. Radiobiological characterization of 53 human tumor cell lines. Int J Radiat Biol. 1989;56:553-560.
26. Fertil B, Malaise EP. Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves. Int J Radiat Oncol Biol Phys. 1985;11:1699-1707.
27. Terry NH, Meistrich ML, Roubein LD, Lynch PM, Dubrow RA, Rich TA. Cellular kinetics in rectal cancer. Br J Cancer. 1995;72:435-141.
28. Tsang RW, Fyles AW, Kirkbride P, et al. Proliferation measurements with flow cytometry Tpot in cancer of the uterine cervix: correlation between two laboratories and preliminary clinical results. Int J Radiat Oncol Biol Phys. 1995;32:1319-1329.
29. Bolger BS, Symonds RP, Stanton PD, et al. Prediction of radiotherapy response of cervical carcinoma through measurement of proliferation rate. Br J Cancer. 1996;74:122.3-1226.
30. Bourhis J, Dendale R, Hill C, et al. Potential doubling time and clinical outcome in head and neck squamous cell carcinoma treated with 70 Gy in 7 weeks. Int J Radiat Oncol Biol Phys. 1996;35:471-476.
31. Bardiès M, Chatal JF. Absorbed fractions of 22 potential beta-emitting radionuclides for internal radiotherapy. Phys Med Biol. 1994;39:961-981.
32. Dale RG. Radiobiological assessment of permanent implants using tumor repopulation factors in the linear-quadratic model. Br J Radiol. 1989;62:241-244.
33. Fowler JF. Radiobiological aspects of low dose rates in radioimmunotherapy. Int J Radiat Oncol Biol Phys. 1990;18:1261-1269.
34. O'Donoghue JA. The impact of tumor cell proliferation in radioimmunotherapy. Cancer. 1994;73(suppl):974s-980s.
35. Hall EJ, Brenner DJ. The dose-rate effect revisited: radiobological considerations of importance in radiotherapy. Int J Radiat Oncol Biol Phys. 1991;21:1403-1414.
36. Williams JR, Zhang YG, Dillehay LE. Sensitization processes in human tumor cells during protracted irradiation: possible exploitation in the clinic. Int J Radiat Oncol Biol Phys. 1992;24:699-704.
37. Shen S, DeNardo GL, Jones TD, et al. A preliminary cell kinetics model of thrombocytopenia after radioimmunotherapy. J Nucl Med. 1998;39:1223-1229.
38. Humm JL, Cobb LM. Nonuniformity of tumor dose in radioimmunotherapy. J Nucl Med. 1990;31:75-83.
39. O'Donoghue JA. The implications of nonuniform tumor doses for radioimmunotherapy. J Nucl Med. 1999;40:1337-1341.
40. O'Donoghue JA, Bardiès M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with β-emitting radionuclides. J Nucl Med. 1995;36:1902-1909.